Canakinumab 150 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 150 mg/mL

Reference Brands: Ilaris (USA/EU)

Category: Immune Disorder

Canakinumab is a monoclonal antibody that targets interleukin-1β to reduce inflammation in various autoinflammatory disorders. It is used for conditions such as CAPS, Still’s disease, gout flares, and certain periodic fever syndromes. The drug is administered subcutaneously in controlled doses according to the specific indication.

Product Description:

Canakinumab is a human monoclonal antibody that binds interleukin-1 beta and neutralises it. IL-1 beta is the master cytokine of the innate immune system's inflammatory response, and in the autoinflammatory diseases it sits at the centre of the problem: inflammasome mutations cause uncontrolled IL-1 beta release, producing fever, rash, joint pain and, over time, amyloidosis.

It is used for cryopyrin-associated periodic syndromes, familial Mediterranean fever and other periodic fever syndromes, systemic juvenile idiopathic arthritis and adult-onset Still's disease, and in some markets for gout flares where other treatments cannot be used. Its half-life is long, so dosing is every four or eight weeks — a considerable advantage in children who would otherwise need frequent injections. Because it blocks a core innate immune pathway, infection risk rises: serious bacterial infections occur, tuberculosis must be excluded before starting, and live vaccines are avoided. Injection site reactions are common.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain at 2 to 8°C. Very high annual cost against small patient numbers means access usually runs through named-patient routes or national rare disease programmes rather than ordinary tenders. Genetic confirmation of the syndrome is generally required for reimbursement.